Core Viewpoint - Libang Pharmaceutical (Jiangsu) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and HTSC acting as joint sponsors [1]. Company Overview - Libang Pharmaceutical is a global leader in biopharmaceuticals focused on kidney disease, possessing the most comprehensive innovative product portfolio in this field, with a wide range of indications [4]. - The chronic kidney disease (CKD) market is substantial, valued at several hundred billion dollars, indicating significant growth potential [4]. - The company has established a vertically integrated platform encompassing research and development, production, and commercialization [4]. Product Pipeline - The company has shifted its focus from hyperphosphatemia to the entire kidney disease sector, addressing unmet medical needs for patients affected by kidney diseases [4]. - As of October 27, 2025, the product pipeline includes seven candidate products (three in clinical stages) and one commercialized product [4]. - The core product, AP301, is a potential best-in-class phosphate binder for treating hyperphosphatemia, having completed Phase III clinical trials in China and currently undergoing global Phase III trials [4]. Financial Performance - For the fiscal years ending June 30, 2024, and June 30, 2025, the company reported revenues of approximately RMB 6.525 million and RMB 12.112 million, respectively [6]. - Research and development expenditures for the fiscal years 2023, 2024, and the first half of 2025 were approximately RMB 307.461 million, RMB 235.367 million, and RMB 110.061 million, respectively [6]. - The company reported a pre-tax loss of RMB 365.256 million for 2023, RMB 335.130 million for 2024, and RMB 209.662 million for the first half of 2025 [7].
新股消息 | 礼邦医药递表港交所 核心产品AP301已完成中国III期注册临床试验
智通财经网·2025-10-31 13:26